Previously we identified a transcription factor, LPS-Induced TNF-␣ Factor (LITAF), mediating inflammatory cytokine expression in LPS-induced processes. To characterize the role of LITAF in vivo, we generated a macrophage-specific LITAF-deficient mouse (macLITAF ؊/؊ ). Our data demonstrate that in macrophages (i) several cytokines (such as TNF-␣, IL-6, sTNF-RII, and CXCL16) are induced at lower levels in macLITAF ؊/؊ compared with LITAF ؉/؉ control macrophages; (ii) macLITAF ؊/؊ mice are more resistant to LPS-induced lethality. To further identify LITAF signaling pathways, we tested mouse TLR-2 ؊/؊ , -4 ؊/؊ , and -9 ؊/؊ and WT peritoneal macrophages exposed to LPS. Using these cells, we now show that LITAF expression can be induced after challenge either with LPS from Porphyromonas gingivalis via agonism at TLR-2, or with LPS from Escherichia coli via agonism at TLR-4, both requiring functional MyD88. We also show that, in response to LPS, the MyD88-dependent LITAF pathway differs from the NF-B pathway. Furthermore, using a kinase array, p38␣ was found to mediate LITAF phosphorylation and the inhibition of p38␣ with a p38-specific inhibitor (SB203580) blocked LITAF nuclear translocation and reduced LPS-induced TNF-␣ protein levels. Finally, mac-LITAF ؊/؊ macrophages rescued by LITAF cDNA transfection restored levels of TNF-␣ similar to those observed in WT cells. We conclude that LITAF is an important mediator of the LPS-induced inflammatory response that can be distinguished from NF-B pathway and that p38␣ is the specific kinase involved in the pathway linking LPS͞MyD88͞LITAF to TNF. macrophage-specific ͉ knockout mouse ͉ Toll-like receptor ͉ myeloid differentiation factor 88 ͉ p38␣ L PS is a major integral structural component of the outer membrane of Gram-negative bacteria, and one of the most potent initiators of inflammation known. LPS activates monocytes and macrophages to produce cytokines such as TNF-␣, IL-1, and IL-6 that, in turn, serve as endogenous inflammatory mediators (1, 2). Previously, we identified a transcription factor, LPS-induced TNF-␣ factor (LITAF), mediating the expression of inflammatory cytokines such as TNF-␣ in LPS-induced processes (3). LITAF was found to bind to STAT6B, a member of the STAT6 family forming a complex on the TNF-␣ promoter that modulates TNF activity (4, 5).
L
PS is a major integral structural component of the outer membrane of Gram-negative bacteria, and one of the most potent initiators of inflammation known. LPS activates monocytes and macrophages to produce cytokines such as TNF-␣, IL-1, and IL-6 that, in turn, serve as endogenous inflammatory mediators (1, 2) . Previously, we identified a transcription factor, LPS-induced TNF-␣ factor (LITAF), mediating the expression of inflammatory cytokines such as TNF-␣ in LPS-induced processes (3) . LITAF was found to bind to STAT6B, a member of the STAT6 family forming a complex on the TNF-␣ promoter that modulates TNF activity (4, 5) .
It is well known that the Toll-like receptors (TLRs) are integral components of the innate immune system, recognizing the presence of microbial invaders via molecules such as LPS (6) (7) (8) (9) . Recent studies indicate that TLRs share the capacity to bind the intracellular myeloid differentiation factor 88 (MyD88) (10, 11) . This interaction of TLRs with MyD88 is involved in several well characterized pathways, including MyD88͞IL-1R-associated kinase (IRAK)͞TNF receptor-associated factor 6 (TRAF6) and the MAPK pathway (12, 13) . More recently, studies have indicated that the 5-lipoxygenase-activating protein (FLAP) can act as a MyD88 partner and activator of NF-B (14, 15) , and that the flightless I homolog protein is a negative regulator of the TLR4-MyD88 pathway via its interaction with MyD88 (16) . Therefore, identifying and characterizing the multiple proteins that function as MyD88 downstream partners should clarify the mechanisms through which specificity is conferred upon different TLR-mediated signaling pathways and further elucidate the LITAF signaling pathway.
The role of LITAF in vivo and its signal transduction pathway in LPS-induced inflammatory processes remain poorly defined. To characterize the role of LITAF in vivo, we generated a macLI-TAF Ϫ/Ϫ mouse in which LITAF is selectively ablated in macrophages. The signal transduction pathway involved in LPS-induced LITAF expression was further elucidated by using peritoneal macrophages extracted from these mice. Overall, our findings reveal a unique LITAF signaling pathway separate from NFkB and help to delineate its roles in the regulation of various inflammatory cytokines in response to LPS stimulation in mouse macrophages.
Results
Generation of macLITAF ؊/؊ Macrophages. The innate immune function of LITAF in vivo was investigated after generating mice lacking LITAF in macrophages (macLITAF Ϫ/Ϫ ) using the Cre-loxP system (Fig. 8 , which is published as supporting information on the PNAS web site) (17) . Western blot analysis showed that macLITAF Ϫ/Ϫ macrophages did not contain LITAF protein (Fig. 1, lanes 4 and 5) even after stimulation with Escherichia coli or Porphyromonas gingivalis LPS, in marked contrast to the response of cells from LITAF ϩ/ϩ control mouse macrophages (lanes 2 and 3). Moreover, transient transfection of macLITAF Ϫ/Ϫ macrophages with pcDNAmusLITAF expression vector enhanced TNF-␣ protein levels (Fig. 2a ). This finding is in agreement with our previous results showing that LITAF specifically activates TNF-␣ gene expression (18).
Cytokine Responses in LITAF-Deficient Macrophages. The levels of several cytokines were investigated by using an antibody array after macrophage stimulation with 0.1 g͞ml of E. coli LPS (Fig. 2b) . After stimulation, the levels of seven cytokines were at least 40% lower (44% for CXCL16, 42% for IL-6, 53% for LIX, 86% for MIP-1r, 50% for sTNF-RII, 52% for G-CSF, and 40% for RAN-TES) in culture supernatants from macLITAF Ϫ/Ϫ macrophages, than from cultures of LITAF ϩ/ϩ macrophages.
LITAF Deficiency and Endotoxic Shock. The importance of LITAF in response to LPS in vivo was determined by comparing LPS-induced lethality in macLITAF Ϫ/Ϫ and LITAF ϩ/ϩ control mice. After i.p. injection with D-galactosamine (D-GalN), followed by 0.25 g of E. coli LPS per mouse, the animals were closely monitored. In murine models, it is well accepted that D-Ga1N dramatically sensitizes mice to the lethal effects of LPS via its toxic effects on hepatocytes (19). There is agreement that death in LPS͞D-GalN-challenged animals is due to TNF toxicity (20) such that D-GalN-sensitized LITAF ϩ/ϩ mice are sensitive to the lethal effect of LPS at a 100-fold lower dose than are unsensitized littermates (21) . As shown in Fig. 2c and Table  1 , which is published as supporting information on the PNAS web site, most deaths occurred between 4 and 8 h with proportions surviving in the two groups remaining quite parallel after that time. At 8 h, 11 of the initial 17 macLITAF Ϫ/Ϫ animals remained alive (64.7%), and only 4 of the 14 initial LITAF ϩ/ϩ control mice (28.6%). No animals were censored or lost to follow-up. 2 analysis gave a P value of 0.045. At 24 h, 9 of the initial 17 macLITAF Ϫ/Ϫ animals remained alive (52.9%), and only 3 of the initial 14 LITAF ϩ/ϩ control mice (21.43%).
2 analysis gave a P value of 0.073.
TLR Engagement in LITAF Signaling. The LPS-dependent signaling pathway leading to LITAF activation was analyzed by investigating LITAF levels in response to LPS stimulation in mouse macrophages of various genotypes (TLR-2 Ϫ/Ϫ , -4 Ϫ/Ϫ , -9 Ϫ/Ϫ , MyD88 Ϫ/Ϫ , and WT controls) using Western blotting. No significant differences were observed in TLR-2 or -4 expression after LPS treatment, between macrophages either lacking LITAF or WT macrophages (Fig. 9 , which is published as supporting information on the PNAS web site, lanes 7 and 8 or lanes 1 and 2). (Fig. 3c) , suggesting that NF-B mediates half of LPS-induced TNF-␣ production. On the other hand, LITAF alone or with another partner such as STAT6B (5) mediates the another half of LPS-induced TNF-␣ production. Furthermore, inhibition of NF-B activation by BAY 11-7082 did not affect LPS-induced LITAF translocation into the nucleus ( LITAF translocation in nucleus was tested in lysates from elutriated human monocytes and analyzed by both kinase array and Western blot. The phosphorylation levels of p38␣͞␦, Hsp27, or ERK1͞2 were significantly increased in LPS-treated cells (Fig. 4 a and b) relative to untreated controls (Fig. 4a) . Additionally, to determine the kinases involved in LITAF translocation, 20 available kinase inhibitors were tested, and the inhibition of LITAF nuclear translocation was analyzed by Western blot. Only SB203580, which specifically inhibits the p38 MAP kinase (23), completely blocked LITAF translocation, whereas in the whole cell, LITAF expression was unchanged (Fig. 4c, lane 5 ). No other inhibitor tested showed any effects. These results demonstrate that the p38 MAP kinase, RayBiotech, Norcross, GA) were blotted with equal amounts of conditioned medium from macrophages (macLITAF Ϫ/Ϫ or LITAF ϩ/ϩ as control) after treatment with 0.1 g͞ml E. coli LPS, and were assessed according to the array manufacturer's protocol. Cytokine array experiments were performed three times, and the intensities of the relative expression levels of cytokines were quantified by densitometry (VerSaDoc Imaging System; Bio-Rad). All cytokine expression levels were normalized with positive signals obtained with biotin-conjugated IgG. The density value of each test sample was calculated and graphed. (c). MacLITAF Ϫ/Ϫ mice were more resistant to LPS-induce septic shock. Survival after LPS administration is shown. Age-matched male macLITAF Ϫ/Ϫ (n ϭ 17) and LITAF ϩ/ϩ mice (n ϭ 14) were injected i.p. with LPS (0.25 g per mouse). Mortality was assessed every hour for 24 h. macLITAF Ϫ/Ϫ mice showed improved survival compared with LITAF ϩ/ϩ ; P Ͻ 0.05. See Table 1 .
p38␣, participates in the phosphorylation of LITAF, and when inhibited by SB203580, LITAF does not translocate into the nucleus to activate cytokines including TNF-␣ and that LITAF is unable to be activated in the absence of p38␣. LITAF phosphorylation. To investigate whether p38␣ activity was MyD88-dependent, proteins extracted from LPS-treated or untreated human monocytes or murine macrophages (WT or MyD88 Ϫ/Ϫ ) were analyzed by Western blot with antibodies against LITAF, MyD88, p38␣, phospho-p38, or actin as control ( Fig. 5 a  and b) . The results showed that LPS-induced p38␣ phosphorylation͞activation is independent of MyD88 (Fig. 5b, lane 2 vs. 4) . Furthermore, the influence of p38␣ phosphorylation on LITAF nuclear translocation was investigated by both kinase array and Western blot analysis. Treatment of human monocytes with 20 M SB203580 for 8-16 h significantly reduced both p38␣ protein and phosphorylation levels ( Fig. 6 a and b, lanes 2-4) , thereby blocking LITAF translocation into the nucleus (Fig. 6b lanes 2-4 and d) .
There was no effect on LPS-induced LITAF protein levels in whole cells (Fig. 6b, lanes 2-4) in comparison to SB203580-untreated controls (lanes 6-8). To further examine whether p38␣ is involved in LITAF activation, we measured TNF-␣ by ELISA after treatment of mouse LITAF ϩ/ϩ and macLITAF Ϫ/Ϫ macrophages with LPS and͞or SB203580. In some cases, macLITAF Ϫ/Ϫ macrophages were first transiently transfected with 0.5 g of pcDNA-musLITAF expression vector DNA to restore LITAF expression. Transient overexpression of LITAF DNA strongly induced production of TNF-␣ (Fig. 6d , condition no. 4, 78% for LITAF ϩ/ϩ cells and 75% for macLITAF Ϫ/Ϫ cells) compared with the LPS-induced cells. However, TNF-␣ production was significantly reduced when transfectants were treated with SB203580 (25% reduction for LITAF ϩ/ϩ cells, 23% for macLITAF Ϫ/Ϫ cells, Fig. 6d , condition no. 8). Additionally, no significant changes in TNF-␣ levels were observed in macLITAF Ϫ/Ϫ cells either treated with LPS alone (Fig. 6d , condition no. 2) or cotreated with SB203580 and LPS (condition no. 5) or with SB203580, LPS, and LITAF DNA (condition no. 7), demonstrating that p38␣ is involved in LPS-induced TNF-␣ production in LITAF ϩ/ϩ cells but not in LITAF-deficient cells.
Discussion
The present results have contributed to our understanding of the mechanism of LITAF expression leading to proinflammatory cytokine production. Namely, (i) inflammatory cytokines are induced at lower levels in macLITAF Ϫ/Ϫ macrophages than in LITAF ϩ/ϩ control macrophages, whereas the restoration of the LITAF gene in macLITAF Ϫ/Ϫ macrophages rescues the deficiency; (ii) macrophage-specific LITAF-deficient mice are resistant to LPS-induced lethality. Although some LITAF-deficient mice did not survive LPS treatment advocating for the involvement of other transcription factors such as NFkB in this process, as a group they fared significantly better than WT mice. These data highlight the important participation of LITAF in an early response to endotoxin, and suggest the possibility of cytokine regulation through LITAF as a therapeutic intervention in LPS and TNF pathophysiological dysfunctions such as rheumatoid arthritis, Crohn's disease, innate immune dysregulation in CNS, or inflammatory changes in mesenteric fat. Indeed, recently we demonstrated a marked increase of LITAF expression in intestinal tissues obtained from patients with Crohn's disease compared with noninflamed matched control tissues (24) .
Because TLRs are integral components of the innate immune system after LPS stimulation, and most TLRs share the capacity to bind to intracellular MyD88 (8, 9), we were interested in determining whether LITAF expression was induced by LPS through TLRs. Here we demonstrated that LITAF expression could be obtained after challenge with either the TLR2 agonist P. gingivalis LPS or the TLR4 agonist E. coli LPS; TLR9 is not involved. We also showed that both of these LPS-induced, LITAF-related signaling pathways converge at MyD88, as demonstrated by the absence of LITAF induction in cells lacking MyD88.
Several studies indicated that NF-B is an important factor linking the MyD88-mediated signaling pathways (11) . Because our studies showed that MyD88 is also involved in the LITAF signaling pathway, it was of particular interest to investigate whether LITAF production depends on NF-B activity in macrophages. The data presented here permit the conclusion that LITAF and NFkB have separate induction pathways that are not affected by each other. Several lines of evidence support this conclusion. No significant changes of NF-B gene expression level were observed in response to the transient overexpression of LITAF in either macLITAF Ϫ/Ϫ or LITAF ϩ/ϩ macrophages (data not shown). Also, we found that BAY 11-7082, which specifically inhibits NF-B (c-Rel, p52, or p50) activation, did not alter LPS-induced LITAF production (Fig. 3b) and translocation (Fig. 4c) even as it reduced TNF-␣ levels in either macLITAF Ϫ/Ϫ or LITAF ϩ/ϩ macrophages (Fig. 3c) . It is well known that macrophage cells are pivotal in innate immune response, particularly where TLRs are sentinel receptors for microbial pathogens. Upon engagement with different microbial ligands, different TLRs initiate a canonical signal transduction where MyD88 serves as an adaptor protein at the downstream of TLRs. TLRs recruits MyD88 and subsequently IRAKs. Then the activated IRAK1 is released from receptor complex and forms complex with TRAF6, which mediates activation of MAPK and NF-B forming the following signaling pathway, MyD88-IRAK-TRAF6-NIK-IB͞NFB as well as MAPK (12, 13) . Recently, a newly identified protein, FLAP-1, was found to be a NF-B linking MyD88-FLAP-1-NF-B (14, 15) . However, although LITAF expression was found to be MyD88-dependent, neither LITAF production nor LITAF-induced TNF production was found to be affected by NFB inhibitor BAY 11-7082. Therefore, we propose that LITAF does not directly link to MyD88-dependent NF-B activation and conclude that the MyD88-dependent LITAF pathway differs from the MyD88-dependent NF-B pathway in response to LPS. Taken together, these findings indicate that TLR-2͞4-mediated signaling pathway involves MyD88 is an adaptor upstream of LITAF and, in turn, LITAF nuclear translocation regulates TNF-␣ gene expression. This pathway seems different from the characterized pathways such as MyD88-IRAK-TRAF6 and MyD88-FLAP-1-NF-B
As for other transcription factors, phosphorylation is an important event for translocation from cytoplasm to nucleus. Indeed, recently, we reported that, upon LPS stimulation, LITAF binds to STAT6B as a heterodimer and subsequently the complex LITAF-STAT6(B) translocates into the nucleus where it significantly increases transcription of several inflammatory cytokines (5). Additionally, it is well known that the STAT family of transcription factors translocate from cytoplasm to nucleus, where they are phosphorylated and become homo-or heterodimers (25) . We wanted to establish whether a specific kinase induced by LPS is required for LITAF phosphorylation and translocation. Thus, a kinase array was used in this study to identify this kinase. It was clearly observed that signals from phosphorylated forms of p38␣͞␦, Hsp27, or ERK1͞2 were significantly increased in LPS-treated cells compared with controls (Fig. 4b) . To confirm this, a panel of kinase-specific inhibitors was tested. Only inhibition of p38 MAP kinase by SB203580 completely blocked LPS-induced LITAF translocation into the nucleus in comparison to controls, whereas LITAF protein levels were unaffected. Because p38␦ was not affected in response to LITAF translocation (data not shown), it suggests that p38␣, and not p38␦ or other kinases, participates in the phosphor- ylation of LITAF. Additionally, the changes of p38␣ protein and phosphorylation levels detected from the LPS-treated or untreated macrophages (WT or MyD88 Ϫ/Ϫ ) indicate that both p38␣ production and LPS-induced p38␣ phosphorylation are MyD88-independent. Interestingly, the p38␣ phosphorylation level reached a peak at 8 h after LPS treatment and then gradually declined, whereas the p38␣ protein level was not changed during this time, a time-course that is similar to the protein level changes for LITAF translocation reported by Tang et al. (5) . This finding shows that p38␣ activation upon LPS stimulation results in LITAF phosphorylation͞activation in human monocytic cells as well as mouse macrophages.
Analysis of the effects of p38␣ on LITAF-dependent TNF-␣ secretion in LITAF ϩ/ϩ or macLITAF Ϫ/Ϫ macrophages showed that LPS-induced TNF-␣ levels were reduced by 30% in macLITAF Ϫ/Ϫ cells compared with LITAF ϩ/ϩ cells. Furthermore, no significant changes of TNF-␣ protein levels were observed in macLITAF Ϫ/Ϫ cells either treated with LPS alone or cotreated with SB203580 plus LPS or SB203580 plus LPS plus LITAF DNA). In addition, the TNF-␣ secretion was strongly induced after LITAF DNA transfection in LITAF ϩ/ϩ and macLITAF Ϫ/Ϫ cell, but significantly reduced (by Ͼ75%) after SB203580 treatment. Because SB203580 is a specific inhibitor of p38␣ MAP kinase, we conclude that p38␣ is the kinase specifically involved in the LITAF͞TNF-␣ pathway in response to LPS stimulation.
Together, the present data provide evidence for the activation of the pathway connecting TLR-2͞4, MyD88, p38␣, LITAF, and TNF-␣ upon LPS stimulation (Fig. 7) . This pathway highlights the multiple sites of potential therapeutic interventions, including regulation of p38␣, aimed at reducing the deleterious events associated with inflammatory conditions and should be instrumental in the design and development of target agents affecting LITAF activity.
Experimental Procedures
Bacteria and Cell Lines. All bacterial cloning constructs used E. coli strain DH5␣ (Invitrogen, Carlsbad, CA). Strain 381 of P. gingivalis was grown in brain heart infusion broth with hemin (5 g͞ml) and menadione (1 g͞ml) in an anaerobic atmosphere (85% N 2 ͞10% H 2 ͞5% CO 2 ) for 24-48 h at 37°C before preparation of LPS as we have described (26) . The human monocytes, purchased from AB (Columbia, MD) were grown in RPMI medium 1640 supplemented with 10% FBS and were maintained in a humidified atmosphere of 5% CO 2 at 37°C. strains, and their corresponding WT controls were obtained from S. Akira (Osaka University, Osaka, Japan). The LITAF conditional knockout mouse strain (macLITAF Ϫ/Ϫ ) was generated as described below. LITAF ϩ/ϩ animal were used as WT animals. All animals were maintained at the Boston University transgenic facility. Mice used in experiments were 8-12 weeks of age, and were kept under strict specific pathogen-free (SPF) conditions. All procedures involving animals were approved by the Institutional Animal Care and Use Committee at Boston University Medical Center.
Macrophages. Details regarding macrophages are given in Supporting Text, which is published as supporting information on the PNAS web site.
LPS Purification and Stimulation in Macrophages.
E. coli LPS serotype O55:B5 LPS (catalog no. L2880; Sigma, St. Louis, MO) was dissolved in PBS (5 mg͞ml) by sonication for 2 min, aliquoted, and stored at Ϫ80°C until use. P. gingivalis LPS (P. gingivalis 381) was purified as described (26) . All LPS preparations were free of protein or lipoprotein contaminants. The precultured macrophages were washed with PBS once and resuspended in 1 ml of RPMI medium 1640 with 10% FCS. The cells were stimulated with 100 ng͞ml LPS (E. coli or P. gingivalis) for 3 h and washed with PBS once, then maintained in a humidified atmosphere of 5% CO 2 at 37°C overnight.
Plasmid Constructs. The mouse LITAF DNA (GenBank accession no. AF230522) in-frame DNA fragments were generated from a mouse spleen cDNA library (Stratagene, La Jolla, CA) by PCR with the primers 5Ј-AAGATGTCTAATGAGCCACC-3Ј and 5Ј-TTAGCACAAGCGCTTGTATG-3Ј, and subcloned into the pCDNA3 vector (Invitrogen) to generate pcDNA-musLITAF expression vector.
Generation of LITAF Conditional Knockout Mice. A mouse ES-129 P1 genomic library (Genome Systems, St. Louis, MO) was screened with the mouse LITAF cDNA. A 4.2-kb HindIII-NaeI fragment containing exons 2-4 of the mouse LITAF gene was subcloned into a modified pGEM-3Zf vector (Promega, Madison, WI). The targeting vector was made by inserting the first loxP site 1 kb upstream of exon 2, and inserting the second loxP site 1 kb downstream of exon 4. The loxP sites were used for the homologous recombination. A 2-kb neomycin resistance cassette (neo) was inserted between the first loxP site and exon 2. J1 embryonic stem (ES) cells were electroporated with the linearized targeting construct. The ES cells were scored for homologous recombination by Southern blotting. EcoRI-digested genomic DNAs were hybridized with a 3-kb SacI-DNA 5Ј probe that contained a partial LITAF gene. Positive clones containing both loxP sites plus the neomycin gene (Neo) were screened as described (29) . Clone 156 (of 264 ES cells screened) harboring a homologous recombination was identified. This clone was injected into C57BL͞6 blastocysts, and two chimeric mice successfully transmitted the floxed (fl) LITAF allele through the germ line. F 1 LITAF fl/ϩ mice were intercrossed to generate (5) are induced by P. gingivalis LPS via TLR-2 or by E. coli LPS via TLR-4. Their production is MyD88-dependent. Subsequently, they are phosphorylated by p38␣ before protein-protein interactions aimed at forming a complex. This phosphorylation leads to the sequestration of the complex in the cytoplasm before translocation of the molecules to the nucleus. In the nucleus, the complex most likely separates to allow for LITAF alone to bind to the specific sequence (CTCCC) (4) of various cytokine genes and thus to activate their transcription.
